InnoCan Pharma (INNO) AI Stock Analysis

• Market Cap: $53.99M
• Dividend Yield: N/A
• Average Volume (3M): 920.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -3.94%
• EPS Growth: -17.62%
• Country: CA
• Employees: 11
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.60
• Shares Outstanding: 4,498,772
• 10 Day Avg. Volume: 392
• 30 Day Avg. Volume: 920
• PEG Ratio: 0.34
• Price to Book (P/B): 7.71
• Price to Sales (P/S): 1.35
• P/FCF Ratio: -25.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: C$9.50 ▼(-5.09% Downside)

InnoCan Pharma's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and cash flow issues. The technical analysis further highlights bearish trends, with the stock trading below key moving averages and indicators in oversold territory. Additionally, the negative P/E ratio and absence of a dividend yield suggest poor valuation. These factors collectively result in a low overall stock score.

InnoCan Pharma Business Overview & Revenue Model

Company Description

InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.

How the Company Makes Money

InnoCan Pharma generates revenue through several key streams, primarily by developing and commercializing cannabinoid-based pharmaceutical products. The company monetizes its research and development efforts by partnering with other pharmaceutical firms and healthcare organizations to co-develop products, which often includes licensing agreements. Additionally, InnoCan may earn revenue from product sales once its therapies and wellness products are approved for market use. The company also benefits from grants and funding aimed at supporting innovative medical research, which further contributes to its financial stability.

InnoCan Pharma Financial Statement Overview

Summary

InnoCan Pharma faces significant financial challenges, with declining revenues, negative profitability, and cash flow issues. Although it maintains a strong gross profit margin and low leverage, it struggles with operational efficiency and shareholder returns.

Income Statement

InnoCan Pharma's income statement shows a high gross profit margin of 88.45% TTM, indicating strong product profitability. However, the company is struggling with negative net profit margins and declining revenue growth, with a TTM revenue decrease of 5.38%. The EBIT and EBITDA margins are positive but low, suggesting limited operational efficiency.

Balance Sheet

The balance sheet reveals a manageable debt-to-equity ratio of 0.33 TTM, indicating low leverage. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating shareholder returns. The equity ratio is not provided, but the overall financial health appears weak due to negative equity in previous years.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and accounting profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.83M	29.44M	13.66M	2.56M	196.00K	8.00K
Gross Profit	25.50M	26.19M	11.98M	2.11M	121.00K	3.00K
EBITDA	675.00K	961.00K	-3.77M	-3.85M	-10.04M	-9.90M
Net Income	-1.58M	-1.83M	-4.70M	-3.89M	-10.06M	-15.18M
Balance Sheet
Total Assets	11.04M	9.26M	6.94M	6.98M	12.57M	4.33M
Cash, Cash Equivalents and Short-Term Investments	7.25M	5.01M	3.88M	4.95M	11.05M	2.34M
Total Debt	1.40M	10.00K	33.00K	34.00K	1.00K	38.00K
Total Liabilities	4.35M	2.24M	2.55M	751.00K	3.56M	7.94M
Stockholders Equity	4.21M	5.17M	4.10M	6.39M	9.05M	-3.61M
Cash Flow
Free Cash Flow	-469.00K	-1.59M	-3.95M	-6.09M	-6.67M	-3.69M
Operating Cash Flow	-453.00K	-1.58M	-3.90M	-6.07M	-6.63M	-3.69M
Investing Cash Flow	53.00K	54.00K	-84.00K	-31.00K	-48.00K	0.00
Financing Cash Flow	2.41M	2.70M	2.92M	125.00K	15.30M	4.02M

InnoCan Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Negative. The current price of 10.01 is below the 20-day moving average (MA) of 14.64, below the 50-day MA of 16.06, and below the 200-day MA of 13.52, indicating a bearish trend. The MACD of -1.56 indicates Positive momentum. The RSI at 18.32 is Positive, neither overbought nor oversold. The STOCH value of 23.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:INNO.

InnoCan Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
MDP	57 Neutral	C$86.45M	64.48	0.87%	―	2.14%	-83.06%
MPH	54 Neutral	C$13.98M	-4.08	-18.39%	―	24.30%	-68.60%
RVV	46 Neutral	C$4.19M	-0.38	-664.21%	―	―	-80.42%
BNXT	41 Neutral	$82.84M	―	―	―	-62.34%	9.80%
INNO	38 Underperform	$53.99M	―	-71.80%	―	-3.94%	-17.62%
MVMD	35 Underperform	C$3.52M	―	-148.48%	―	-46.59%	8.26%

InnoCan Pharma Corporate Events

Innocan Pharma to Showcase Innovative Pain Management Platform at 2025 ThinkEquity Conference

Innocan Pharma announced its participation in the 2025 ThinkEquity Conference, where it will present its innovative LPT-CBD injectable platform for chronic pain management. This participation provides Innocan with a valuable opportunity to share business updates and explore new market opportunities, potentially enhancing its industry positioning and stakeholder engagement.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$15.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Innocan Pharma Secures Patent for LPT-CBD in Japan, Strengthening Global IP Portfolio

Innocan Pharma announced that its patent for the Liposomal CBD Injection Technology (LPT-CBD) has been allowed in Japan, marking a significant milestone in the world’s third-largest pharmaceutical market. This patent, which covers a prolonged-release formulation of synthetic CBD, strengthens Innocan’s global intellectual property portfolio and supports its positioning as a leader in non-opioid chronic pain management solutions. The development of LPT-CBD, in collaboration with experts from the Hebrew University in Jerusalem, has shown promising results in preclinical studies, and the company is advancing towards FDA approval, potentially impacting its market presence and offering a new alternative for chronic pain management.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$13.00 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Innocan Pharma’s LPT-CBD Injections Transform Animal Care at Freedom Farm

Innocan Pharma has partnered with Freedom Farm to provide its LPT-CBD injections for animals suffering from chronic pain, significantly improving their quality of life. This collaboration highlights Innocan’s commitment to compassionate care and the potential of its technology to transform pain management in animals and humans, as demonstrated by the successful treatment of two goats at the sanctuary.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$12.00 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Innocan Pharma’s CBD Technology Gains Traction at PAINWeek Conference

Innocan Pharma’s presentation on its Liposomal Synthetic CBD Technology at the PAINWeek conference generated significant interest among participants, highlighting the potential of LPT-CBD as a breakthrough in chronic pain management. The presentation emphasized the limitations of plant-derived CBD oils and showcased preclinical data supporting the prolonged pain relief capabilities of LPT-CBD, marking a promising advancement in the field.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$12.00 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Innocan Pharma Announces Share Consolidation Ahead of NASDAQ Listing

Innocan Pharma has announced a share consolidation as a strategic step towards a public offering in the United States and listing on the NASDAQ Capital Market. This move is expected to reduce the number of common shares significantly and is part of the company’s broader plan to enhance its market presence and attract new investors.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Innocan Pharma Reports Improved Profitability Amid Market Challenges

Innocan Pharma reported its financial results for the first half of 2025, highlighting a significant improvement in operating profitability despite a slight decline in revenue due to global trade tariffs. The company is focused on strategic growth in multiple markets, offering opioid-free chronic pain relief and exploring opportunities for a U.S. public offering on the Nasdaq Capital Market. Innocan is also advancing its LPT-CBD platform for chronic pain treatment, with promising pre-clinical results supporting its ongoing development.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.

Innocan Pharma Showcases Non-Opioid Pain Solution at PAINWeek 2025

Innocan Pharma Corporation is set to showcase its innovative LPT-CBD platform at the PAINWeek 2025 conference in Las Vegas, highlighting its potential as a non-opioid solution for chronic pain management. The company’s participation in this prestigious event underscores its commitment to advancing pain care and positions Innocan at the forefront of non-opioid chronic pain management solutions, offering a promising alternative to opioid medications.

The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.